SCHEMBL21037550

SCHEMBL21037550

CC1OC(=O)OC1(C)Oc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.36
GAA P10253 1/20 0.36
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31
MMP9 P14780 1/20 0.31
MMP8 P22894 1/20 0.31
MMP13 P45452 1/20 0.31
KMT2A Q03164 2/20 0.31
GRM2 Q14416 1/20 0.31
CTSV O60911 1/20 0.31
CTSL P07711 1/20 0.31
CTSB P07858 1/20 0.31
CTSH P09668 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21037554 0.71
SCHEMBL21037551 0.68
SCHEMBL6427016 0.68 PLA2G7 (0.36) NPSR1GAAL3MBTL1HTTSMN1; SMN2
SCHEMBL11654282 0.66 GAA (0.41) NPSR1GAAPOLBHTTMMP2
SCHEMBL1324048 0.64 POLB (0.42) NPSR1GAALMNAPOLBL3MBTL1
SCHEMBL27985910 0.63 CA4 (0.36) NPSR1GAASMN1; SMN2KMT2AMEN1
SCHEMBL7598877 0.63 CA4 (0.36) NPSR1GAA
SCHEMBL22883567 0.63
SCHEMBL4962250 0.63 HTR1A (0.36)
SCHEMBL21037547 0.63 ALDH1A1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11916195-B2 Electrolyte solution, electrochemical device, lithium ion secondary battery, and module DAIKIN INDUSTRIES, LTD. (JP) 2024-02-27 US disclosed
US-11916195-B2 Electrolyte solution, electrochemical device, lithium ion secondary battery, and module DAIKIN INDUSTRIES, LTD. (JP) 2024-02-27 US disclosed
US-11718599-B2 Method for producing cyclic carbonate having unsaturated group, and novel cyclic carbonate DAIKIN INDUSTRIES, LTD. (JP) 2023-08-08 US disclosed
US-11718599-B2 Method for producing cyclic carbonate having unsaturated group, and novel cyclic carbonate DAIKIN INDUSTRIES, LTD. (JP) 2023-08-08 US disclosed
US-11664534-B2 Electrolytic solution, electrochemical device, lithium ion secondary battery, and module DAIKIN INDUSTRIES, LTD. (JP) 2023-05-30 US disclosed
US-11664534-B2 Electrolytic solution, electrochemical device, lithium ion secondary battery, and module DAIKIN INDUSTRIES, LTD. (JP) 2023-05-30 US disclosed
US-20210384556-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2021-12-09 US disclosed
US-20210198228-A1 METHOD FOR PRODUCING CYCLIC CARBONATE HAVING UNSATURATED GROUP, AND NOVEL CYCLIC CARBONATE DAIKIN INDUSTRIES, LTD. (JP) 2021-07-01 US disclosed
EP-3780230-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2021-02-17 EP disclosed
US-20210043974-A1 ELECTROLYTE SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2021-02-11 US disclosed
EP-3764451-A1 ELECTROLYTE SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2021-01-13 EP disclosed
US-20200280096-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2020-09-03 US disclosed
EP-3670502-A1 METHOD FOR PRODUCING CYCLIC CARBONATE HAVING UNSATURATED GROUP, AND NOVEL CYCLIC CARBONATE Daikin Industries, Ltd. (JP) 2020-06-24 EP disclosed
WO-2019102722-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE ダイキン工業株式会社 2019-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200280096-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE RER1, NDUFA10, NDUFB10 NPSR1 4054/4885GAA 2965/4885LMNA 2107/4885
US-11718599-B2 Method for producing cyclic carbonate having unsaturated group, and novel cyclic carbonate ADH1C, ADH1A, F12 NPSR1 1935/4885GAA 4260/4885LMNA 1826/4885
US-11664534-B2 Electrolytic solution, electrochemical device, lithium ion secondary battery, and module RER1, NDUFA10, NDUFB10 NPSR1 4054/4885GAA 2965/4885LMNA 2107/4885
US-20210198228-A1 METHOD FOR PRODUCING CYCLIC CARBONATE HAVING UNSATURATED GROUP, AND NOVEL CYCLIC CARBONATE ADH1C, ADH1A, F12 NPSR1 1935/4885GAA 4260/4885LMNA 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.